Format

Send to

Choose Destination
Nutr Cancer. 2020;72(1):74-87. doi: 10.1080/01635581.2019.1619783. Epub 2019 Jun 1.

Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland: A Randomized Controlled Trial.

Author information

1
Division of Hematology and Oncology, Oregon Health & Science University, Portland, Oregon, USA.
2
Department of Urology, Portland Veterans Administration Medical Center, Oregon Health & Science University, Portland, Oregon, USA.
3
School of Biological and Population Health Science, Oregon State University, Corvallis, Oregon, USA.
4
Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
5
Linus Pauling Institute, Oregon State University, Corvallis, Oregon, USA.
6
Department of Pathology and Laboratory Medicine, Oregon Health and Science University, Portland, Oregon, USA.
7
Environmental and Molecular Toxicology, Oregon State University, Corvallis, Oregon, USA.
8
Center for Epigenetics & Disease Prevention, Texas A&M College of Medicine, Houston, Texas, USA.
9
Department of Biochemistry and Biophysics, Oregon State University, Corvallis, Oregon, USA.
10
The School of Electrical Engineering and Computer Science, Oregon State University, Corvallis, Oregon, USA.
11
Moore Family Center for Whole Grain Foods, Nutrition and Preventive Health, Oregon State University, Corvallis, Oregon, USA.

Abstract

Previous studies suggest compounds such as sulforaphane (SFN) derived from cruciferous vegetables may prevent prostate cancer development and progression. This study evaluated the effect of broccoli sprout extract (BSE) supplementation on blood histone deacetylase (HDAC) activity, prostate RNA gene expression, and tissue biomarkers (histone H3 lysine 18 acetylation (H3K18ac), HDAC3, HDAC6, Ki67, and p21). A total of 98 men scheduled for prostate biopsy were allocated into either BSE (200 µmol daily) or a placebo in our double-blind, randomized controlled trial. We used nonparametric tests to evaluate the differences of blood HDAC activity and prostate tissue immunohistochemistry biomarkers between treatment groups. Further, we performed RNA-Seq analysis on the prostate biopsies and identified 40 differentially expressed genes correlated with BSE treatment, including downregulation of two genes previously implicated in prostate cancer development, AMACR and ARLNC1. Although urine and plasma SFN isothiocyanates and individual SFN metabolites were statistically higher in the treatment group, our results did not show a significant difference in HDAC activity or prostate tissue biomarkers. This study indicates BSE supplementation correlates with changes in gene expression but not with several other prostate cancer biomarkers. More research is required to fully understand the chemopreventive effects of BSE supplementation on prostate cancer.

Supplemental Content

Loading ...
Support Center